SRR12696729
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- INTERFERON_ALPHA_RESPONSE+0.500
- INTERFERON_GAMMA_RESPONSE+0.500
- COMPLEMENT+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_UP+0.300
- TGF_BETA_SIGNALING+0.300
- UV_RESPONSE_DN+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.300
- CHOLESTEROL_HOMEOSTASIS-0.200
- E2F_TARGETS-0.200
- GLYCOLYSIS-0.200
- HEDGEHOG_SIGNALING-0.200
- KRAS_SIGNALING_DN-0.200
- PANCREAS_BETA_CELLS-0.200
- UV_RESPONSE_UP-0.200
- FATTY_ACID_METABOLISM-0.100
- G2M_CHECKPOINT-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934745 | — | — | 0.859 |
| 2 | BS_49VCQD19 | Neurofibroma | — | 0.857 |
| 3 | C3N-03765 | — | cohortA1 | 0.850 |
| 4 | BS_9HA238XS | Neurofibroma | — | 0.850 |
| 5 | ERR2208956 | — | — | 0.849 |
| 6 | TCGA-50-5941-01A-11R-1755-07 | — | cohortA1 | 0.841 |
| 7 | TCGA-50-5049-01A-01R-1628-07 | — | cohortA1 | 0.829 |
| 8 | SRR10900571 | — | — | 0.828 |
| 9 | SRR26320064 | — | — | 0.828 |
| 10 | SJBT031026_D1.RNA-Seq | EPN | Spinal EPN | 0.828 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.500 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.500 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.100 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |